세계의 악성 흉막중피종 시장 : 약제 유형별, 투여 경로별, 유통경로별, 지역별, 국가별 분석, 시장 인사이트, 예측

Global Malignant Pleural Mesothelioma Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast

US $ 2,450 ￦ 3,406,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 2,950 ￦ 4,101,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 악성 흉막중피종 시장 규모는 2020-2023년에 CAGR로 4.98%의 성장을 보이며, 2023년에 6억 4,899만 달러에 달하며, 2030년에 10억 4,569만 달러에 달할 것으로 예측됩니다.

세계의 악성 흉막중피종 시장은 복수의 주요 요인에 의해 예측 기간에 큰 성장을 보일 것으로 예측됩니다. 가장 두드러진 촉진요인 중 하나는 석면 관련 질환의 발병률 증가, 특히 역사적으로 석면이 사용되어 온 지역에서 석면 관련 질환의 발병률이 증가하고 있다는 점입니다. 세계보건기구(WHO)에 따르면 석면은 여전히 중피종의 주요 원인이며, 특정 지역에서 지속적인 위험이 명시되어 있습니다.

면역치료나 유전자 치료와 같은 혁신적인 치료법도 환자들에게 치료 결과를 개선하고 새로운 희망을 제공함으로써 시장 확대에 기여하고 있습니다. 이러한 새로운 치료법은 특히 선진국에서 큰 호응을 얻고 있으며, 첨단 의료 인프라가 첨단 치료법의 채택을 지원하고 있습니다. 또한 인식 증가는 조기 발견율 향상에 기여하고, 이러한 치료법의 효과를 더욱 높이고 있습니다.

또한 신흥 시장의 의료 인프라가 확대됨에 따라 첨단 진단 및 치료 옵션에 대한 접근성이 확대되면서 시장 성장에 박차를 가하고 있습니다.

세계의 악성 흉막중피종 시장에 대해 조사했으며, 시장 규모와 예측, 지역과 부문 분석, 주요 동향과 기회 등의 정보를 제공하고 있습니다.

목차

제1장 시장 배경

• 범위와 제품 전망
• 개요
• 조사 방법

제2장 애널리스트의 권장사항

• 새로운 투여 경로 임상시험의 확대
• 아시아태평양과 라틴아메리카에서 신흥 시장의 활용

제3장 세계의 악성 흉막중피종 시장 : 실적과 예측

• 악성 흉막중피종 시장에 대한 거시경제 요인의 영향 분석
• 석면 수출 상위자 : 국가별(2021년)
• 석면 수입 상위자 : 국가별(2021년)
• 중피종의 유병률과 이환율(2018-2021년)
• 세계의 악성 흉막중피종 시장 : 대시보드
• 세계의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
• 세계의 악성 흉막중피종 시장 : 시장 금액의 평가
• 세계의 악성 흉막중피종 시장 부문 : 약제 유형별
  • 세계의 악성 흉막중피종 시장 : 약제 유형별, 개요
  • 세계의 악성 흉막중피종 시장의 매력 지수 : 약제 유형별
  • 세계의 악성 흉막중피종 시장 규모 : Pemetrexed, 병용(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : Cisplatin(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : Carboplatin(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : Gemcitabine(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : Vinorelbine(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : 기타 약제 유형(2020-2030년)
• 세계의 악성 흉막중피종 시장 부문 : 투여 경로별
  • 세계의 악성 흉막중피종 시장 : 투여 경로별, 개요
  • 세계의 악성 흉막중피종 시장의 매력 지수 : 투여 경로별
  • 세계의 악성 흉막중피종 시장 규모 : 경구(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : 비경구(2020-2030년)
• 세계의 악성 흉막중피종 시장 부문 : 유통 채널별
  • 세계의 악성 흉막중피종 시장 : 유통 채널별, 개요
  • 세계의 악성 흉막중피종 시장의 매력 지수 : 유통 채널별
  • 세계의 악성 흉막중피종 시장 규모 : 병원 약국(2020-2030년)
  • 세계의 악성 흉막중피종 시장 규모 : 소매 약국, 온라인 약국(2020-2030년)

제4장 악성 흉막중피종 시장, 지역 분석

• 조사의 지역 범위
• 지역의 스냅숏

제5장 아메리카의 악성 흉막중피종 시장 : 실적과 예측

• 아메리카의 악성 흉막중피종 시장 : 스냅숏
• 아메리카의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
• 아메리카의 악성 흉막중피종 시장 : 주요 요인
• 아메리카의 악성 흉막중피종 시장 : 부문 분석
• 아메리카의 악성 흉막중피종 시장 부문 : 약제 유형별
• 아메리카의 악성 흉막중피종 시장 부문 : 투여 경로별
• 아메리카의 악성 흉막중피종 시장 부문 : 유통 채널별
• 아메리카의 악성 흉막중피종 시장 부문 : 국가별
  • 아메리카의 악성 흉막중피종 시장 : 국가별, 개요
  • 미국의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 캐나다의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 기타 아메리카의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)

제6장 유럽의 악성 흉막중피종 시장 : 실적과 예측

• 유럽의 악성 흉막중피종 시장 : 스냅숏
• 유럽의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
• 유럽의 악성 흉막중피종 시장 : 주요 요인
• 유럽의 악성 흉막중피종 시장 : 부문 분석
• 유럽의 악성 흉막중피종 시장 부문 : 약제 유형별
• 유럽의 악성 흉막중피종 시장 부문 : 투여 경로별
• 유럽의 악성 흉막중피종 시장 부문 : 유통 채널별
• 유럽의 악성 흉막중피종 시장 부문 : 국가별
  • 유럽의 악성 흉막중피종 시장 : 국가별, 개요
  • 영국의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 독일의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 프랑스의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 이탈리아의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 스페인의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 기타 유럽의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)

제7장 아시아태평양의 악성 흉막중피종 시장 : 실적과 예측

• 아시아태평양의 악성 흉막중피종 시장 : 개요
• 아시아태평양의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
• 아시아태평양의 악성 흉막중피종 시장 : 주요 요인
• 아시아태평양의 악성 흉막중피종 시장 : 부문 분석
• 아시아태평양의 악성 흉막중피종 시장 부문 : 약제 유형별
• 아시아태평양의 악성 흉막중피종 시장 부문 : 투여 경로별
• 아시아태평양의 악성 흉막중피종 시장 부문 : 유통 채널별
• 아시아태평양의 악성 흉막중피종 시장 부문 : 국가별
  • 아시아태평양의 악성 흉막중피종 시장 : 국가별, 개요
  • 중국의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 인도의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 일본의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
  • 기타 아시아태평양의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)

제8장 중동 및 아프리카의 악성 흉막중피종 시장 : 실적과 예측

• 중동 및 아프리카의 악성 흉막중피종 시장 : 스냅숏
• 중동 및 아프리카의 악성 흉막중피종 시장 : 시장 규모와 CAGR(2020-2030년)
• 중동 및 아프리카의 악성 흉막중피종 시장 : 주요 요인
• 중동 및 아프리카의 악성 흉막중피종 시장 : 부문 분석
• 중동 및 아프리카의 악성 흉막중피종 시장 부문 : 약제 유형별
• 중동 및 아프리카의 악성 흉막중피종 시장 부문 : 투여 경로별
• 중동 및 아프리카의 악성 흉막중피종 시장 부문 : 유통 채널별

제9장 시장 역학

• 악성 흉막중피종 시장에 대한 시장 역학의 영향 평가
• 촉진요인
• 억제요인
• 동향

제10장 산업 에코시스템 분석

• Porter의 산업 분석

제11장 경쟁 포지셔닝

• 기업의 제품 포지셔닝
• 시장 포지션 매트릭스
• 악성 흉막중피종 시장의 시장 점유율 분석
• 기업 개요
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc
  • Eli Lily & Co.
  • Pfizer
  • Novartis
  • Teva Pharmaceuticals
  • GSK plc
  • AstraZeneca PLC
  • Bayer AG

제12장 Azoth Analytics 및 면책사항

KSA

영문 목차

영문목차

Executive Summary

Azoth Analytics has released a research report titled "Global Malignant Pleural Mesothelioma Market (2024 Edition)" which provides a Pemetrexed and Combination analysis of the Global Malignant Pleural Mesothelioma industry in terms of market segmentation By Drug Type (Pemetrexed and Combination, Cisplatin), By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Malignant Pleural Mesothelioma market showcased growth at a CAGR of 4.98% during 2020-2023. The market was valued at USD 648.99 Million in 2023 which is expected to reach USD 1045.69 Million in 2030.

The global Malignant Pleural Mesothelioma market is projected to experience significant growth during the forecast period, driven by several key factors. Among the most prominent drivers is the increasing incidence of asbestos-related diseases, particularly in regions with historical asbestos use. According to the World Health Organization (WHO), asbestos remains the primary cause of mesothelioma, underscoring the persistent risk in certain regions.

Innovative treatment options, such as immunotherapy and gene therapy, are also contributing to market expansion by offering improved outcomes and new hope for patients. These novel therapies are gaining traction, especially in developed regions, where advanced healthcare infrastructure supports the adoption of cutting-edge treatments. Rising awareness campaigns are helping improve early detection rates, further enhancing the effectiveness of these therapies.

Furthermore, the growing healthcare infrastructure in emerging markets is enabling greater access to advanced diagnostic and treatment options, fueling market growth.

Scope of the Report:

• The report analyses the Malignant Pleural Mesothelioma Market by Value (USD Million).
• The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
• The report presents the analysis of Malignant Pleural Mesothelioma Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Malignant Pleural Mesothelioma Market By Drug Type (Pemetrexed and Combination, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Other Drug Types)
• The report analyses the Malignant Pleural Mesothelioma Market By Route of Administration (Oral, and Parenteral).
• The report analyses the Malignant Pleural Mesothelioma Market By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type, By Route of Administration and By Distribution Channel.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Bristol Myers Squibb, F. Hoffmann-La Roche AG, Merck & Co., Inc, Eli Lily & Co., Pfizer, Novartis, Teva Pharmaceuticals, GSK plc, AstraZeneca PLC, and Bayer AG

Table of Contents

1. Market Background

• 1.1 Scope and Product Outlook
• 1.2 Executive Summary
• 1.3 Research Methodology

2. Analyst Recommendations

• 2.1 Expanding Clinical Trials for Novel Route of Administration
• 2.2 Capitalizing on Emerging Markets in Asia-Pacific and Latin America

3. Global Malignant Pleural Mesothelioma Market: Historic and Forecast

• 3.1 Impact Analysis of Macro Economic Factors on Malignant Pleural Mesothelioma Market
• 3.2 Top exporters of Asbestos by country in 2021
• 3.3 Top Importer of Asbestos by country in 2021
• 3.4 Prevalence and Incidence of Mesothelioma 2018-2021
• 3.5 Global Malignant Pleural Mesothelioma Market: Dashboard
• 3.6 Global Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 3.7 Global Malignant Pleural Mesothelioma Market: Market Value Assessment
• 3.8 Global Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
  • 3.8.1 Global Malignant Pleural Mesothelioma Market, By Drug Type Overview
  • 3.8.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Drug Type
  • 3.8.3 Global Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.4 Global Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.5 Global Malignant Pleural Mesothelioma Market Size, By Carboplatin , By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.6 Global Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.7 Global Malignant Pleural Mesothelioma Market Size, By Vinorelbine , By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.8 Global Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
• 3.9 Global Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
  • 3.9.1 Global Malignant Pleural Mesothelioma Market, By Route of Administration Overview
  • 3.9.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Route of Administration
  • 3.9.3 Global Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9.4 Global Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 3.10 Global Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
  • 3.10.1 Global Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
  • 3.10.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Distribution Channel
  • 3.10.3 Global Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10.4 Global Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

4. Malignant Pleural Mesothelioma Market, Region Analysis

• 4.1 Regional Coverage of the Study
• 4.2 Regional Snapshot

5. Americas Malignant Pleural Mesothelioma Market: Historic and Forecast

• 5.1 Americas Malignant Pleural Mesothelioma Market: Snapshot
• 5.2 Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 5.3 Americas Malignant Pleural Mesothelioma Market: Key Factors
• 5.4 Americas Malignant Pleural Mesothelioma Market: Segment Analysis
• 5.5 Americas Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
  • 5.5.1 Americas Malignant Pleural Mesothelioma Market, By Drug Type Overview
  • 5.5.2 Americas Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.3 Americas Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.4 Americas Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.5 Americas Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.6 Americas Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.7 Americas Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
• 5.6 Americas Malignant Pleural Mesothelioma Market Segmentation: Route of Administration
  • 5.6.1 Americas Malignant Pleural Mesothelioma Market, By Route of Administration Overview
  • 5.6.2 Americas Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.6.3 Americas Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 5.7 Americas Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
  • 5.7.1 Americas Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
  • 5.7.2 Americas Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7.3 Americas Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
• 5.8 Americas Malignant Pleural Mesothelioma Market Segmentation: By Country
  • 5.8.1 Americas Malignant Pleural Mesothelioma Market, by Country Overview
  • 5.8.2 United States Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.8.2.1 United States Malignant Pleural Mesothelioma Market, By Drug Type
    • 5.8.2.2 United States Malignant Pleural Mesothelioma Market, By Route of Administration
    • 5.8.2.3 United States Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 5.8.3 Canada Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.8.3.1 Canada Malignant Pleural Mesothelioma Market, By Drug Type
    • 5.8.3.2 Canada Malignant Pleural Mesothelioma Market, By Route of Administration
    • 5.8.3.3 Canada Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 5.8.4 Rest of Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.8.4.1 Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type
    • 5.8.4.2 Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration
    • 5.8.4.3 Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel

6. Europe Malignant Pleural Mesothelioma Market: Historic and Forecast

• 6.1 Europe Malignant Pleural Mesothelioma Market: Snapshot
• 6.2 Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 6.3 Europe Malignant Pleural Mesothelioma Market: Key Factors
• 6.4 Europe Malignant Pleural Mesothelioma Market: Segment Analysis
• 6.5 Europe Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
  • 6.5.1 Europe Malignant Pleural Mesothelioma Market, By Drug Type Overview
  • 6.5.2 Europe Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.3 Europe Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.4 Europe Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.5 Europe Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.6 Europe Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.7 Europe Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
• 6.6 Europe Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
  • 6.6.1 Europe Malignant Pleural Mesothelioma Market, By Route of Administration Overview
  • 6.6.2 Europe Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.6.3 Europe Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 6.7 Europe Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
  • 6.7.1 Europe Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
  • 6.7.2 Europe Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7.3 Europe Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
• 6.8 Europe Malignant Pleural Mesothelioma Market Segmentation: By Country
  • 6.8.1 Europe Malignant Pleural Mesothelioma Market, by Country Overview
  • 6.8.2 United Kingdom Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.2.1 United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.2.2 United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.2.3 United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 6.8.3 Germany Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.3.1 Germany Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.3.2 Germany Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.3.3 Germany Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 6.8.4 France Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.4.1 France Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.4.2 France Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.4.3 France Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 6.8.5 Italy Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.5.1 Italy Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.5.2 Italy Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.5.3 Italy Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 6.8.6 Spain Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.6.1 Spain Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.6.2 Spain Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.6.3 Spain Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 6.8.7 Rest of Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.8.7.1 Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type
    • 6.8.7.2 Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration
    • 6.8.7.3 Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel

7. Asia Pacific Malignant Pleural Mesothelioma Market: Historic and Forecast

• 7.1 Asia Pacific Malignant Pleural Mesothelioma Market: Snapshot
• 7.2 Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 7.3 Asia Pacific Malignant Pleural Mesothelioma Market: Key Factors
• 7.4 Asia Pacific Malignant Pleural Mesothelioma Market: Segment Analysis
• 7.5 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
  • 7.5.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type Overview
  • 7.5.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.4 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.5 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.6 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.7 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
• 7.6 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
  • 7.6.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration Overview
  • 7.6.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.6.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 7.7 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
  • 7.7.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
  • 7.7.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
• 7.8 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Country
  • 7.8.1 Asia Pacific Malignant Pleural Mesothelioma Market, by Country Overview
  • 7.8.2 China Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.8.2.1 China Malignant Pleural Mesothelioma Market, By Drug Type
    • 7.8.2.2 China Malignant Pleural Mesothelioma Market, By Route of Administration
    • 7.8.2.3 China Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 7.8.3 India Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.8.3.1 India Malignant Pleural Mesothelioma Market, By Drug Type
    • 7.8.3.2 India Malignant Pleural Mesothelioma Market, By Route of Administration
    • 7.8.3.3 India Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 7.8.4 Japan Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.8.4.1 Japan Malignant Pleural Mesothelioma Market, By Drug Type
    • 7.8.4.2 Japan Malignant Pleural Mesothelioma Market, By Route of Administration
    • 7.8.4.3 Japan Malignant Pleural Mesothelioma Market, By Distribution Channel
  • 7.8.5 Rest of Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.8.5.1 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type
    • 7.8.5.2 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration
    • 7.8.5.3 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel

8. Middle East and Africa Malignant Pleural Mesothelioma Market: Historic and Forecast

• 8.1 Middle East and Africa Malignant Pleural Mesothelioma Market: Snapshot
• 8.2 Middle East and Africa Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 8.3 Middle East and Africa Malignant Pleural Mesothelioma Market: Key Factors
• 8.4 Middle East and Africa Malignant Pleural Mesothelioma Market: Segment Analysis
• 8.5 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
  • 8.5.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Drug Type Overview
  • 8.5.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.4 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.5 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.6 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.7 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
• 8.6 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
  • 8.6.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Route of Administration Overview
  • 8.6.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.6.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 8.7 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
  • 8.7.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
  • 8.7.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

• 9.1 Impact assessment of Market Dynamics on Malignant Pleural Mesothelioma Market
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Trends

10. Industry Ecosystem Analysis

• 10.1 Porter Analysis

11. Competitive Positioning

• 11.1 Companies' Product Positioning
• 11.2 Market Position Matrix
• 11.3 Market Share Analysis of Malignant Pleural Mesothelioma Market
• 11.4 Company Profiles
  • 11.4.1 Bristol Myers Squibb
  • 11.4.2 F. Hoffmann-La Roche AG
  • 11.4.3 Merck & Co., Inc
  • 11.4.4 Eli Lily & Co.
  • 11.4.5 Pfizer
  • 11.4.6 Novartis
  • 11.4.7 Teva Pharmaceuticals
  • 11.4.8 GSK plc
  • 11.4.9 AstraZeneca PLC
  • 11.4.10 Bayer AG

12. About Us & Disclaimer

관련자료